mhurhangee/ep-ind-claims huggingface dataset:
A power semiconductor device comprising: a power semiconductor circuit section; a plurality of smoothing capacitors; a positive electrode conductor portion and a negative electrode conductor portion connecting the power semiconductor circuit section and the plurality of smoothing capacitors; and a sealing material that seals the power semiconductor circuit section, the plurality of smoothing capacitors, the positive electrode conductor portion, and the negative electrode conductor portion, wherein the plurality of smoothing capacitors form a capacitor circuit section sandwiched between the positive electrode conductor portion and the negative electrode conductor portion, the power semiconductor circuit section has a first exposure surface exposed from the sealing material and a second exposure surface that is exposed from the sealing material and provided on a side opposite to the first exposure surface, a plane with which the first exposure surface overlaps is defined as a first plane, and a plane with which the second exposure surface overlaps is defined as a second plane, the capacitor circuit section is formed so as to fit in a space between the first plane and the second plane, and the positive electrode conductor portion or the negative electrode conductor portion forms a concave portion to accommodate a part of each of the plurality of smoothing capacitors. a power semiconductor circuit section; a plurality of smoothing capacitors; a positive electrode conductor portion and a negative electrode conductor portion connecting the power semiconductor circuit section and the plurality of smoothing capacitors; and a sealing material that seals the power semiconductor circuit section, the plurality of smoothing capacitors, the positive electrode conductor portion, and the negative electrode conductor portion, wherein the plurality of smoothing capacitors form a capacitor circuit section sandwiched between the positive electrode conductor portion and the negative electrode conductor portion, the power semiconductor circuit section has a first exposure surface exposed from the sealing material and a second exposure surface that is exposed from the sealing material and provided on a side opposite to the first exposure surface, a plane with which the first exposure surface overlaps is defined as a first plane, and a plane with which the second exposure surface overlaps is defined as a second plane, the capacitor circuit section is formed so as to fit in a space between the first plane and the second plane, and the positive electrode conductor portion or the negative electrode conductor portion forms a concave portion to accommodate a part of each of the plurality of smoothing capacitors.
Injector for implantation of an intraocular lens, having a base body and an elongated actuation element, which projects at least partly into a rear section of the base body and which is movably guided in an actuation axis, and wherein a movement of the actuation element into the base body can be generated selectively by means of a push actuation along the actuation axis or by means of a screw actuation about the actuation axis, and wherein the actuation element features an external thread at least on one section, wherein a switch element is arranged to the base body, whereas the switch element is rotatable about the actuation axis or is displaceable in the actuation axis, whereas the switch element features at least one spring arm, having a thread engagement structure on an inner surface facing the external thread, whereas at the base body is formed an inner surface, which forms an operative contact with an outer surface of the spring arm, whereas the inner surface and/or the outer surface is formed inclined to the actuation axis at an angle (α) or the inner surface features an inner radius (Ri) varying at least in sections in a circumferential direction about the actuation axis, so that upon rotation or upon displacement of the switch element an elastic deformation of the spring arm towards the actuation axis and away from the actuation axis can be generated, whereby the thread engagement structure can be selectively engaged or disengaged with the external thread.
A method for determining whether a subject not undergoing statin treatment is at risk to develop one or more CVD complications, such as acute myocardial infarction and/or CVD death, comprising a. determining in a sample from said subject one or more lipid-lipid concentration ratio(s), wherein (an) increased or decreased lipid-lipid concentration ratio(s) in said sample, when compared to a control sample, is (are) indicative of said subject having an increased risk of developing one or more CVD complications, such as AMI or CVD death, wherein the one or more lipid-lipid concentration ratio(s) whose increase(s) is (are) compared to the control is (are) selected from: Cer(d18:1/18:0)/Cer(d18:1/24:0), Cer(d18:1/20:0)/Cer(d18:1/24:0), and Cer(d18:1/22:0)/Cer(d18:1/24:0); and wherein the one or more lipid-lipid concentration ratio(s) whose decrease(s) is (are) compared to the control is (are) selected from: Cer(d18:1/24:0)/Cer(d18:1/24:1), Cer(d18:1/24:0)/PC 16:0/18:2, Cer(d18:1/24:0)/SM (d18:1/14:0) (d18:1/13:1-OH), Cer(d18:1/24:0)/Gb3(d18:1/16:0) and Cer(d18:1/24:0)/SM (d18:1/16:1) (d18:1/15:2-OH); or b. determining in a sample from said subject a lipid-clinical concentration ratio, wherein a decreased lipid-clinical concentration ratio in said sample, when compared to a control sample, is indicative of said subject having an increased risk of developing one or more CVD complications, such as AMI or CVD death, wherein the lipid-clinical concentration ratio whose decrease is compared to the control is Cer(d18:1/24:0)/supersensitive C-reactive protein. a. determining in a sample from said subject one or more lipid-lipid concentration ratio(s), wherein (an) increased or decreased lipid-lipid concentration ratio(s) in said sample, when compared to a control sample, is (are) indicative of said subject having an increased risk of developing one or more CVD complications, such as AMI or CVD death, wherein the one or more lipid-lipid concentration ratio(s) whose increase(s) is (are) compared to the control is (are) selected from: Cer(d18:1/18:0)/Cer(d18:1/24:0), Cer(d18:1/20:0)/Cer(d18:1/24:0), and Cer(d18:1/22:0)/Cer(d18:1/24:0); and wherein the one or more lipid-lipid concentration ratio(s) whose decrease(s) is (are) compared to the control is (are) selected from: Cer(d18:1/24:0)/Cer(d18:1/24:1), Cer(d18:1/24:0)/PC 16:0/18:2, Cer(d18:1/24:0)/SM (d18:1/14:0) (d18:1/13:1-OH), Cer(d18:1/24:0)/Gb3(d18:1/16:0) and Cer(d18:1/24:0)/SM (d18:1/16:1) (d18:1/15:2-OH); or b. determining in a sample from said subject a lipid-clinical concentration ratio, wherein a decreased lipid-clinical concentration ratio in said sample, when compared to a control sample, is indicative of said subject having an increased risk of developing one or more CVD complications, such as AMI or CVD death, wherein the lipid-clinical concentration ratio whose decrease is compared to the control is Cer(d18:1/24:0)/supersensitive C-reactive protein.
A molecule comprising an antibody Fab fragment that specifically binds human Aβ peptide between amino acid positions 13 to 28, wherein the antibody fragment comprises a light chain variable region of SEQ ID NO: 1 and a heavy chain variable region of SEQ ID NO: 2, and wherein the said antibody Fab fragment is covalently attached to a 20 kD polyethylene glycol molecule at the cysteine at amino acid 56 of SEQ ID NO: 2.
A computer-implemented method for generating one or more radiotherapy treatment plans, the method comprising: receiving a set of pairs of image data for each gantry angle of a radiotherapy treatment machine, wherein each pair of the set of pairs comprises a given projection image that represents a view of an anatomy of a subject from a given gantry angle and a given graphical aperture image of multi-leaf collimator, MLC, leaf positions at the given gantry angle based on the given projection image; training a generative adversarial network, GAN, model based on the set of pairs of image data for each gantry angle; and using the trained GAN model to predict an aperture image of MLC leaf positions for a desired gantry angle based on a projection image that represents a view of an anatomical region of interest. receiving a set of pairs of image data for each gantry angle of a radiotherapy treatment machine, wherein each pair of the set of pairs comprises a given projection image that represents a view of an anatomy of a subject from a given gantry angle and a given graphical aperture image of multi-leaf collimator, MLC, leaf positions at the given gantry angle based on the given projection image; training a generative adversarial network, GAN, model based on the set of pairs of image data for each gantry angle; and using the trained GAN model to predict an aperture image of MLC leaf positions for a desired gantry angle based on a projection image that represents a view of an anatomical region of interest.
An ophthalmic apparatus comprising: an aspiration port through which a fluid including intraocular tissues is aspirated from a patient's eye; a reservoir part for storing the fluid including the intraocular tissues aspirated through the aspiration port; a first aspiration part configured to aspirate air from the reservoir part to decrease internal pressure of the reservoir part to draw the fluid including the intraocular tissues into the reservoir part; a first path extending from the aspiration port through the reservoir part; a second path extending from the aspiration port by detouring around the reservoir part; a second aspiration part connected to the first path and the second path and configured to aspirate the fluid including the intraocular tissues delivered to the first path and the second path; a drain part for collecting the fluid including the intraocular tissues delivered from the second aspiration part; and a switching part configured to switch a pathway for connecting the aspiration port to the second aspiration part between the first path and the second path; wherein the second aspiration part is configured to discharge and deliver the fluid including the intraocular tissues from the reservoir part into the drain part and to aspirate the fluid including the intraocular tissues from the patient's eye and directly deliver it to the drain part. an aspiration port through which a fluid including intraocular tissues is aspirated from a patient's eye; a reservoir part for storing the fluid including the intraocular tissues aspirated through the aspiration port; a first aspiration part configured to aspirate air from the reservoir part to decrease internal pressure of the reservoir part to draw the fluid including the intraocular tissues into the reservoir part; a first path extending from the aspiration port through the reservoir part; a second path extending from the aspiration port by detouring around the reservoir part; a second aspiration part connected to the first path and the second path and configured to aspirate the fluid including the intraocular tissues delivered to the first path and the second path; a drain part for collecting the fluid including the intraocular tissues delivered from the second aspiration part; and a switching part configured to switch a pathway for connecting the aspiration port to the second aspiration part between the first path and the second path; wherein the second aspiration part is configured to discharge and deliver the fluid including the intraocular tissues from the reservoir part into the drain part and to aspirate the fluid including the intraocular tissues from the patient's eye and directly deliver it to the drain part.
A zoom lens system consisting of, in order from an object: a first lens group having negative refractive power; a second lens group having positive refractive power; upon varying a state of lens group positions from a wide-angle end state to a telephoto end state, a distance between the first lens group and the second lens group decreases, the first lens group consisting of, in order from the object side, a first lens having negative refractive power and a second lens having positive refractive power, the second lens group consisting of, in order from the object side, a third lens having positive refractive power, a fourth lens having negative refractive power, and a fifth lens having positive refractive power, and the following conditional expression being satisfied: 0.76 < S 2 / fw < 1.30 where S2 denotes a thickness of the second lens group, and fw denotes a focal length of the zoom lens system in the wide-angle end state, characterised in that the following conditional expression is satisfied: 1.05 < FNw × fw − f 1 < 1.40 where FNw denotes an f-number of the zoom lens system in the wide-angle end state, fw denotes a focal length of the zoom lens system in the wide-angle end state, and f1 denotes a focal length of the first lens group. a first lens group having negative refractive power; a second lens group having positive refractive power; upon varying a state of lens group positions from a wide-angle end state to a telephoto end state, a distance between the first lens group and the second lens group decreases, the first lens group consisting of, in order from the object side, a first lens having negative refractive power and a second lens having positive refractive power, the second lens group consisting of, in order from the object side, a third lens having positive refractive power, a fourth lens having negative refractive power, and a fifth lens having positive refractive power, and the following conditional expression being satisfied: 0.76 < S 2 / fw < 1.30 where S2 denotes a thickness of the second lens group, and fw denotes a focal length of the zoom lens system in the wide-angle end state, characterised in that the following conditional expression is satisfied: 1.05 < FNw × fw − f 1 < 1.40 where FNw denotes an f-number of the zoom lens system in the wide-angle end state, fw denotes a focal length of the zoom lens system in the wide-angle end state, and f1 denotes a focal length of the first lens group.
A compound of formula I Wherein Q1 and Q2 are independently selected from an aryl, a 5-6 membered heterocyclyl or a 9-11 membered bicycloheterocyclyl; Q1 is a halogen when R and R 1 are not presented. Z is N or C-R; R and R 1 are independently selected from H, halogen, halogenC 1 -C 6 alkyl, -C 1 -C 6 alkyl, -OR 7, or-NR 7 R 8; R 2 and R 3 are independently selected from H, halogen, -OH, -C 1 -C 6 alkyl, -C 1 -C 6 alkoxyl, -C 1 -C 6 alkenyl or -C 1 -C 6 alkynyl; R 2 is not -CF3; R 4 and R 5 are independently selected from H, halogen, halogenC 1 -C 6 alkyl, -C 1 -C 6 alkyl, -OH, -C 1 -C 6 alkoxyl, cycloalkyl; or both R 4 and R 5 can be combined together to form a 3-8 membered saturated or unsaturated ring that can be aliphatic cyclyl or heterocyclyl; R 6 is selected from H, -CH 3 or -CN; R 7 and R 8 are independently selected from H, halogen, -C 1 -C 6 alkyl, -C 1 -C 6 alkylOH, -C 1 -C 6 alkoxyl, -C 1 -C 6 alkylNR 4 R 5, -C(=O)C 1 -C 6 alkyl, -C(=O)C 1 -C 6 alkyl-R 4 R 5, -C(=O)C 1 -C 6 alkylOH, -C(=O)C 1 -C 6 alkoxyl, -C(=O)C 1 -C 6 alkylNR 4 R 5, -C(=O)OC 1 -C 6 alkyl, -C(=O)OC 1 -C 6 alkylOH, -C(=O)OC 1 -C 6 alkoxyl, -C(=O)OC 1 -C 6 alkylNR 4 R 5, -C(=O)NR 4 C 1 -C 6 alkyl, -C(=O)NR 4 C 1 -C 6 alkyl-OH, -C(=O)-NR 4 C 1 -C 6 alkoxyl, -C(=O)NR 4 C 1 -C 6 alkylNR 4 R 5; or a pharmaceutically acceptable salt thereof. Q1 and Q2 are independently selected from an aryl, a 5-6 membered heterocyclyl or a 9-11 membered bicycloheterocyclyl; Q1 is a halogen when R and R 1 are not presented. Z is N or C-R; R and R 1 are independently selected from H, halogen, halogenC 1 -C 6 alkyl, -C 1 -C 6 alkyl, -OR 7, or-NR 7 R 8; R 2 and R 3 are independently selected from H, halogen, -OH, -C 1 -C 6 alkyl, -C 1 -C 6 alkoxyl, -C 1 -C 6 alkenyl or -C 1 -C 6 alkynyl; R 2 is not -CF3; R 4 and R 5 are independently selected from H, halogen, halogenC 1 -C 6 alkyl, -C 1 -C 6 alkyl, -OH, -C 1 -C 6 alkoxyl, cycloalkyl; or both R 4 and R 5 can be combined together to form a 3-8 membered saturated or unsaturated ring that can be aliphatic cyclyl or heterocyclyl; R 6 is selected from H, -CH 3 or -CN; R 7 and R 8 are independently selected from H, halogen, -C 1 -C 6 alkyl, -C 1 -C 6 alkylOH, -C 1 -C 6 alkoxyl, -C 1 -C 6 alkylNR 4 R 5, -C(=O)C 1 -C 6 alkyl, -C(=O)C 1 -C 6 alkyl-R 4 R 5, -C(=O)C 1 -C 6 alkylOH, -C(=O)C 1 -C 6 alkoxyl, -C(=O)C 1 -C 6 alkylNR 4 R 5, -C(=O)OC 1 -C 6 alkyl, -C(=O)OC 1 -C 6 alkylOH, -C(=O)OC 1 -C 6 alkoxyl, -C(=O)OC 1 -C 6 alkylNR 4 R 5, -C(=O)NR 4 C 1 -C 6 alkyl, -C(=O)NR 4 C 1 -C 6 alkyl-OH, -C(=O)-NR 4 C 1 -C 6 alkoxyl, -C(=O)NR 4 C 1 -C 6 alkylNR 4 R 5; or a pharmaceutically acceptable salt thereof.
A manufactured wood product in the form of a consolidated monolith comprising a plurality of natural wood pieces adhesively bonded together by a crosslinked thermoplastic adhesive which has been cross linked during processing wherein said manufactured wood product retains its consolidated shape when subjected to a boil test at 100°C-105°C in tap water for 3 hours and wherein the crosslinked thermoplastic adhesive has a glass transition temperature of less than about 70 degrees Celsius.
An actuator system comprising: a first actuator system (302; 312; 322) configured to control an operation of a vehicle body of a vehicle (1; 11; 41); and a second actuator system (304a; 324a) that is configured to control the operation of the vehicle body and is different from the first actuator system (302; 312; 322), wherein the first actuator system (302; 312; 322) comprises: at least one first application (A,B; H) configured to set a first kinematic plan for the vehicle (1; 11; 41); and one or more first processors (302c; 312c, 312d, 312e) configured to arbitrate a plurality of kinematic plans including the first kinematic plan as a first arbitration; characterized in that the second actuator system (304a; 324a) comprises: a second application configured to set a second kinematic plan for the vehicle (1; 11; 41); and a second processor configured to arbitrate an arbitration result by the first arbitration of the first actuator system (302; 312; 322) and the second kinematic plan set by the second application. a first actuator system (302; 312; 322) configured to control an operation of a vehicle body of a vehicle (1; 11; 41); and a second actuator system (304a; 324a) that is configured to control the operation of the vehicle body and is different from the first actuator system (302; 312; 322), wherein the first actuator system (302; 312; 322) comprises: at least one first application (A,B; H) configured to set a first kinematic plan for the vehicle (1; 11; 41); and one or more first processors (302c; 312c, 312d, 312e) configured to arbitrate a plurality of kinematic plans including the first kinematic plan as a first arbitration; characterized in that the second actuator system (304a; 324a) comprises: a second application configured to set a second kinematic plan for the vehicle (1; 11; 41); and a second processor configured to arbitrate an arbitration result by the first arbitration of the first actuator system (302; 312; 322) and the second kinematic plan set by the second application. at least one first application (A,B; H) configured to set a first kinematic plan for the vehicle (1; 11; 41); and one or more first processors (302c; 312c, 312d, 312e) configured to arbitrate a plurality of kinematic plans including the first kinematic plan as a first arbitration; characterized in that the second actuator system (304a; 324a) comprises: a second application configured to set a second kinematic plan for the vehicle (1; 11; 41); and a second processor configured to arbitrate an arbitration result by the first arbitration of the first actuator system (302; 312; 322) and the second kinematic plan set by the second application. a second application configured to set a second kinematic plan for the vehicle (1; 11; 41); and a second processor configured to arbitrate an arbitration result by the first arbitration of the first actuator system (302; 312; 322) and the second kinematic plan set by the second application.
A device which in use is subject to fluid flow, the device including an outer surface part (24b, 25b) the geometry of which is variable to affect the fluid flow, the device including a support structure which supports the outer surface part, the support structure is internal of the outer surface part and includes a plurality of support members of composite material, the support members having a bi-stable geometry that is changeable by an actuating apparatus between a first stable geometry and a second stable geometry to effect variation in the geometry of the outer surface part (24b, 25b), the support members providing structural stiffness to the outer surface part (24b, 25b), and in that the composite material of each support member is a laminated composite material including a plurality of laminate layers (35a - 35d) of fibres embedded in set matrix material, at least one of the laminate layers (35 a - 35 d) including a region (R 1, R 2) of fibres (35a, 35d) which were stressed prior to the matrix material setting, the fibres of the laminate layers of each of the support members of composite material being substantially aligned within that layer, and any fibres (35a, 35d) which are pre-stressed fibres in the or each member extend in a common direction and establish a unidirectional stress field in the internal support structure.